Lurie Cancer Center and Northwestern Medicine Experts to Present at #ASCO21

Jessica Altman, MD

Title: Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.
Abstract Number: 7007
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date and Time: June 4, 2021, 2:30 PM

Massimo Cristofanilli, MD

Title: Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.
Abstract Number: 1000
Session Title: Breast Cancer -- Metastatic
Session Date and Time: June 5, 2021, 12:30 p.m. CDT

Sheetal Kircher, MD

Title: Baseline and short-term financial burden (FB) in colorectal cancer (CRC) treated with curative intent: Early results of ECOG-ACRIN EAQ162CD.
Abstract Number: 1518
Session Title: Care Delivery and Regulatory Policy
Session Date and Time: June 4, 2021, 8:00 a.m. CDT

Devalingam Mahalingam, MD, PhD

Title: Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma.
Abstract Number: 4144
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date and Time: June 4, 2021, 8:00 a.m. CDT

Jyoti Patel, MD

Title: Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.
Abstract Number: 9084
Session Title: Lung Cancer—Non-Small Cell Metastatic
Session Date and Time: June 4, 2021, 8:00 a.m. CDT

David Cella, PhD, FASCO

Title: Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial.
Abstract Number: 4057
Session Title: Health Services Research and Quality Improvement

Title: Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N+C) versus sunitinib (SUN) in treatment-naïve, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data.
Abstract Number: 6567
Session Title: Health Services Research and Quality Improvement
Session Date and Time: June 4, 2021, 8:00 a.m. CDT

Zhou Zhang, PhD

Title: Multi-cancer detection and tissue of origin determination based on 5-hydroxymethylcytosine biomarkers in circulating cell-free DNA.
Abstract Number: 3123
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Session Date and Time: June 4, 2021, 8:00 a.m. CDT

Conor Driscoll, MD

Title: TNF-alpha immunosuppressive use and future malignancy risk.
Abstract Number: 10558
Session Title: Prevention, Risk, Reduction, and Hereditary Cancer
Session Date and Time: June 4, 2021, 8:00 a.m. CDT

Erica Wrubel, MD

Title: Gene methylation and cytological atypia in random fine needle aspirates for assessment of breast cancer risk: 10-year follow up in average risk women.
Abstract Number: 10520
Session Title: Prevention, Risk, Reduction, and Hereditary Cancer
Session Date and Time: June 4, 2021, 8:00 a.m. CDT

Omar Bushara, MD, MPH

Title: HPV-mediated anal squamous cell carcinoma and precancerous lesions in HIV positive patients.
Abstract Number: 3520
Session Title: Gastrointestinal Cancer – Colorectal and Anal
Session Date and Time: June 4, 2021, 8:00 a.m. CDT

Christine Weldon, MBA

Title: Multicancer hereditary syndrome testing: Genetic counselors’ perspectives.
Abstract Number: 10594
Session Title: Prevention, Risk, Reduction, and Hereditary Cancer
Session Date and Time: June 4, 2021, 8:00 a.m. CDT

Maha Hussain, MD

Title: SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).
Abstract Number: 5001
Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile
Session Date and Time: June 8, 2021, 7:00 a.m. CDT

Barbara Pro, MD

Title: Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).
Abstract Number: 7514
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Session Date and Time: June 4, 2021, 8:00 a.m. CDT

Sunandana Chandra, MD

Title: Informing Clinical Practice: Long-Term Updates of Pivotal Trials
Session Title: Melanoma/Skin Cancers
Session Date and Time: June 8, 2021, 7:00 a.m. CDT

William Gradishar, MD

Title: Leveraging Oral Therapy in Advanced Breast Cancer
Session Title: Breast Cancer — Metastatic
Session Date and Time: June 5, 2021, 12:30 p.m. CDT

June McKoy, MD

Title: Understanding Facilitators and Barriers to Geriatric Assessments: Where Do We Go from Here.
Session Title: Symptoms and Survivorship
Session Date and Time: June 4, 2021, 8:00 a.m. CDT

Seema Khan, MD

Title:  Team Players: A Multidisciplinary Approach to the Treatment of Oligometastatic Breast Cancer
Session Title: Case-Based Panel
Session Date and Time: June 4, 2021, 4:00 p.m. CDT

Judith Paice, PhD, RN

Title: Understanding and Managing Chronic Effects of the Cancer Experience
Session: Symptoms and Survivorship